The company Proteomics International Laboratories Ltd. He announced the results of a clinical study showing that a blood test PromarkerD can predict the onset of diabetic kidney disease.
Conclusions presented by Professor Tim Davis of the Medical School of the University of Western Australia in the 77th Annual Scientific Sessions of the American Diabetes Association in San Diego, California.
A study conducted in the framework of cooperation between the Proteomics International and the University of Western Australia, is the largest clinical study of diabetic kidney disease.
Recent results suggest that the analysis predicts PromarkerD rapid decline in renal function in type 2 diabetes regardless of the recognized risk factors.
According to the International Diabetes Federation, in 2015 the disease was found in 415 million adults. The US Center for Disease Control says that one in three diabetic chronic kidney disease. Upon detection of chronic kidney disease can be treated with medication and changes in lifestyle, to slow the progression of the disease and prevent renal failure.
The study confirms the effectiveness of forecasting models of the initial results of a study published in the European Journal of Proteomics in March 2017. Indicator "sensitivity» PromarkerD was 86 percent.
According to Professor Davies data support the use of protein biomarkers in combination with eGFR (estimate glomerular filtration rate) in patients with type 2 diabetes for monitoring and predicting decreased renal function.
"This clinical trial confirms the important role PromarkerD analysis for effective monitoring of patients with diabetes, - said Dr. Richard Lipscomb of Proteomics International -. Although the complications of diabetes patients control, the current tests do not reveal early symptoms of kidney disease, which can lead to the need for dialysis or kidney transplant. "
PromarkerD - blood test, which uses a protein for measurement of renal disease in diabetic patients. This innovative test diagnoses and predicts disease. A published study has shown that diabetic patients already suffering from chronic kidney disease, PromarkerD can diagnose the presence of the disease that was missed at the time of standard assays.
PromarkerD can predict the onset of the disease before the onset of clinical symptoms. In the current study we observed 792 patients. PromarkerD correctly predicted 86 percent of diabetics who develop chronickidney disease .